

# Cameco Corp.

(CCO-T: C\$23.76)

## NEUTRAL

Target: C\$22.00

COMMENT

July 2, 2021

#### Ralph M. Profiti, CFA / (647) 484-8545 rprofiti@viiicapital.com

# Cigar Lake Evacuated; KazAtomProm Maintains 20% Production Curtailment into 2023

| Deting                           | Current             |         |         |         |  |  |
|----------------------------------|---------------------|---------|---------|---------|--|--|
| Rating:<br>Target:               | NEUTRAL<br>C\$22.00 |         |         |         |  |  |
| 5                                |                     |         |         |         |  |  |
| Company Data<br>Last Price (TSX) |                     |         |         | \$23.76 |  |  |
| 52-Week Range:                   | \$11.84 ·           |         |         |         |  |  |
| Market Capitalization (CS        | \$11.04             | 9,448   |         |         |  |  |
| Enterprise Value (C\$MIn)        |                     | 9,420   |         |         |  |  |
| Shares Outstanding - Dil         |                     | 397     |         |         |  |  |
| Dividend Yield:                  |                     |         |         | 0.3%    |  |  |
| Cash                             |                     |         |         | 1.024   |  |  |
| Net Debt                         |                     |         |         | -28     |  |  |
| Fiscal Year End                  |                     |         |         | Dec 31  |  |  |
| Sales Summary                    |                     |         |         |         |  |  |
| Sules Sullinary                  | 2019 A              | 2020 A  | 2021 E  | 2022 E  |  |  |
| Uranium (Mln lbs)                | 35                  | 32      | 30      | 25      |  |  |
| Fuel Services (mm kgU)           | 12                  | 14      | 14      | 12      |  |  |
| NUKEM (mm lbs)                   | 6                   | 2       | 1       | 1       |  |  |
| Financial Summary                |                     |         |         |         |  |  |
|                                  | 2019 A              | 2020 A  | 2021 E  | 2022 E  |  |  |
| P/E                              | n.m.                | n.m.    | n.m.    | n.m.    |  |  |
| EV/EBITDA                        | 25.5x               | 85.3x   | 63.2x   | 35.5x   |  |  |
| CFPS                             | 1.05                | 0.49    | 0.26    | 0.53    |  |  |
| P/CF                             | 22.6x               | 48.2x   | 91.7x   | 44.5x   |  |  |
| Net Debt/ EBITDA                 | n/a                 | 0.7x    | n/a     | n/a     |  |  |
| Quarterly EBITDA                 |                     |         |         |         |  |  |
|                                  | 2019 A              | 2020 A  | 2021 E  |         |  |  |
| Q1                               | 14 A                | 51 A    | 18 A    |         |  |  |
| Q2                               | 43 A                | -4 A    | 18 E    |         |  |  |
| Q3                               | 34 A                | -10 A   | 51 E    |         |  |  |
| Q4<br>FY                         | 277 A               | 71 A    | 61 E    |         |  |  |
| FY                               | 368 A               | 110 A   | 149 E   | 265 E   |  |  |
| Quarterly EPS                    |                     |         |         |         |  |  |
|                                  | 2019 A              | 2020 A  | 2021 E  |         |  |  |
| Q1                               | -0.08 A             | 0.07 A  | -0.08 A |         |  |  |
| Q2                               | -0.04 A             | -0.16 A | -0.07 E |         |  |  |
| Q3                               | -0.01 A             | -0.20 A | 0.02 E  |         |  |  |
| Q4                               | 0.24 A              | 0.12 A  | 0.04 E  |         |  |  |
| FY                               | 0.10 A              | -0.17 A | -0.09 E | 0.10 E  |  |  |
| Note: All values are in CS       |                     |         |         |         |  |  |

Note: All values are in C\$, unless otherwise stated Source: Company Reports, FactSet, Eight Capital Estimates

Cameco Corporation (CCO-CA) Volume (Millions) Price (CAD) Cameco Corporation Volume -6.0 26.0 24.0 5.0 22.0 4.0 20.0 18.0 3.0 16.0 14.0 2.0 12.0 10.0 1.0 8.0 0 6.0 Jul-19 Oct-19 Jan-20 Apr-20 Jul-20 Oct-20 Jan-21 Apr-21

Source: Company Reports, Factset, Eight Capital estimates

#### **Company Description**

Cameco is one of the world's largest uranium producers with mines in Canada, the U.S. and Kazakhstan, and is also a leading provider of nuclear fuel processing services and uranium trading.

**Cigar Lake evacuated**. Spot uranium prices (UxC BAP) were up +\$0.21/lb yesterday following Cameco's decision to evacuate all non-essential personnel from the Cigar Lake uranium mine as a precaution due to the proximity of a northern wildfire that is currently burning in the vicinity of the operation. Roughly 80 essential personnel will remain on site to maintain the facility in a safe state. Should the wildfire threat grow considerably at site, a plan is in place to ensure safety. At full capacity, Cigar Lake accounts for 13% of global uranium mine supply (18Mln lbs/year) and 10% of total global uranium supply (including secondary supplies).

This unforeseen supply event comes at a time when Cameco has been expanding its contract portfolio. In April, Cameco added 9Mln lbs of U3O8 to its long-term contract portfolio. We see Cameco continuing to make open market purchases to meet 2021 uranium deliveries guidance of 23-25Mln lbs and maintain desired level of inventories, which at 1Q21 totaled 11.3Mln lbs. Expected purchases of 11-13Mln lbs by Cameco (guidance) compares to 33.5Mln lbs in 2020.

We do not expect a meaningful industry supply response to tighter uranium markets and higher prices until \$40/lb (at least). KazAtomProm (KAP-L, not rated) released operating guidance today including plans to maintain 2023 production at a similar level to 2022, extending a 20% production curtailment relative to planned volumes under its Subsoil Use Contracts – and essentially keeping approx. 13Mln lbs of uranium supply out of the market until 2023. As a result, Kazakhstan uranium production will remain essentially flat from 2021-2023 at approx. 59Mln lbs.

KAP CEO Galymzhan Pirmatov commented. "Although the uranium market is starting to show signs of improvement, including an increase in long-term contracting interest, a thinning spot market, and slightly improved pricing, we still find ourselves in a position where adding tonnes back into the market in 2023 would be unlikely to maximize returns for our shareholders". In our view, a sustained recovery would be evidenced by tighter supply-demand conditions and prices >\$40/lb, whereby an idle McArthur River (Cameco) restart (22-25Mln lbs/year) and KazAtomProm ramp-up (13Mln lbs/year) remain the largest potential sources on incremental supply, which compares to the current market (2021) in a 6.7Mln lbs deficit; however, we would expect these two parties would let the price "run" >\$40/lb before making a restart decision.

An extended Cigar Lake shutdown would expand our 2021 market deficit. In our view, improving uranium fundamentals as the physical market transitions to deficit combined with relatively low near-term utility contracting requirements makes timing of a price recovery challenging. Our expectations of a partial rebound in primary mine supply of +3.9% in 2021 to 128Mln lbs (COVID-19 restarts, including Cigar Lake, offset by the planned shutdowns of Energy Resources of Australia's (ERA-AX, not rated) Ranger mine and Orano's (private) COMINAK mine in Niger) combined with lower contribution from secondary supplies as commercial destocking declines materially (which incorporates strategic purchases by junior miners and investment funds) is expected to result in a 6.7Mln lb market deficit when factoring in flat uranium demand.

Maintain Neutral; TP C\$22. A premium valuation has long been part of the Cameco investment narrative. Rising cash flow potential on expectations of tightening uranium markets in the long-term, together with a unique market position, with high industry barriers to entry and lack of investment alternatives, has kept valuation at a premium. We estimate Cameco shares are currently pricing in \$63/lb uranium prices at 1x P/NAV and \$53/lb at 1.2x P/NAV – which compares to the UxC LT price of \$32/lb. Our TP of \$22 is based on 1.5x P/NAV (\$14.38/share) and represents a 10% discount vs. Cameco's historical peak P/NAV during uranium "bull markets" of 1.60x. Cameco remains in a very strong financial position with end-1Q21 cash and investments of \$1,024Mln, total debt of \$1Bln (no maturities until 2024 and beyond), and \$1,000Mln of undrawn credit facilities.

# Eight Capital Uranium Supply/Demand Model

| all figures in Mln lbs U3O8, unless noted | 2017  | 2018   | 2019  | 2020   | 2021   | 2022  | 2023   | 2024  | 2025  | 2026   | 2027   | 2028   | 2029   | 2030   |
|---|-------|--------|-------|--------|--------|-------|--------|-------|-------|--------|--------|--------|--------|--------|
| Uranium Supply (MIn Ibs)                  |       |        |       |        |        |       |        |       |       |        |        |        |        |        |
| Africa                                    | 20.0  | 22.9   | 22.9  | 22.0   | 20.2   | 20.2  | 20.7   | 21.2  | 20.9  | 17.8   | 17.8   | 17.8   | 17.8   | 16.4   |
| Australia                                 | 15.2  | 16.6   | 16.5  | 15.3   | 12.5   | 13.0  | 13.0   | 13.0  | 13.0  | 13.0   | 13.0   | 13.0   | 13.0   | 13.0   |
| Canada                                    | 34.1  | 18.2   | 18.0  | 10.6   | 10.2   | 21.4  | 21.4   | 31.8  | 41.9  | 41.9   | 40.4   | 37.3   | 40.3   | 43.3   |
| Kazakhstan                                | 60.6  | 56.3   | 59.0  | 50.0   | 58.9   | 58.9  | 58.9   | 62.2  | 66.2  | 64.8   | 61.7   | 61.1   | 58.1   | 59.3   |
| China                                     | 4.9   | 4.9    | 4.9   | 4.9    | 5.2    | 5.2   | 5.2    | 5.2   | 5.2   | 5.2    | 5.2    | 5.2    | 5.2    | 5.2    |
| Russia                                    | 7.6   | 7.6    | 7.6   | 7.6    | 8.0    | 8.0   | 8.3    | 8.6   | 9.0   | 9.4    | 9.4    | 9.4    | 9.4    | 9.4    |
| United States                             | 2.5   | 1.5    | 0.2   | 0.2    | 0.2    | 0.2   | 0.2    | 0.2   | 0.2   | 0.2    | 2.7    | 5.2    | 5.0    | 5.0    |
| Other Countries                           | 12.1  | 12.2   | 12.7  | 12.8   | 12.9   | 12.9  | 12.9   | 12.9  | 12.9  | 12.9   | 12.9   | 12.9   | 12.9   | 12.9   |
| Primary Supply                            | 156.9 | 140.1  | 141.8 | 123.2  | 128.0  | 139.7 | 140.6  | 155.0 | 169.2 | 165.2  | 163.1  | 161.9  | 161.7  | 164.4  |
| growth rate                               | -4.5% | -10.7% | 1.2%  | -13.1% | 3.9%   | 9.1%  | 0.6%   | 10.3% | 9.1%  | -2.3%  | -1.3%  | -0.8%  | -0.1%  | 1.7%   |
| Secondary supply                          | 56.0  | 70.1   | 60.2  | 63.6   | 45.6   | 41.3  | 38.3   | 35.7  | 34.9  | 30.8   | 27.9   | 26.3   | 25.2   | 19.8   |
| Total supply                              | 212.9 | 210.2  | 202.0 | 186.8  | 173.6  | 180.9 | 178.9  | 190.8 | 204.1 | 196.0  | 191.0  | 188.1  | 186.9  | 184.3  |
| growth rate                               | 0.7%  | -1.3%  | -3.9% | -7.5%  | -7.0%  | 4.2%  | -1.1%  | 6.6%  | 7.0%  | -3.9%  | -2.5%  | -1.5%  | -0.6%  | -1.4%  |
| World Nuclear Generating Capacity (GWe)   |       |        |       |        |        |       |        |       |       |        |        |        |        |        |
| China                                     | 39.4  | 46.6   | 49.2  | 47.5   | 51.5   | 55.5  | 59.5   | 63.5  | 67.5  | 72.5   | 77.5   | 82.5   | 87.5   | 92.5   |
| India                                     | 6.3   | 6.3    | 6.3   | 6.3    | 6.3    | 7.3   | 7.3    | 7.3   | 8.3   | 8.3    | 8.3    | 8.3    | 8.3    | 10.3   |
| Japan                                     | 4.2   | 6.9    | 8.7   | 8.7    | 8.7    | 10.7  | 12.7   | 14.7  | 16.7  | 18.7   | 20.7   | 22.7   | 24.7   | 24.7   |
| Russia                                    | 26.1  | 27.3   | 28.4  | 28.4   | 28.4   | 28.4  | 28.4   | 28.4  | 28.4  | 28.4   | 28.4   | 28.4   | 28.4   | 28.4   |
| USA                                       | 100.0 | 99.3   | 98.2  | 98.2   | 98.2   | 99.4  | 99.4   | 100.7 | 100.7 | 100.7  | 100.7  | 100.7  | 100.7  | 100.7  |
| Other                                     | 182.5 | 186.2  | 188.6 | 185.5  | 185.4  | 190.9 | 193.2  | 197.0 | 199.4 | 200.6  | 200.4  | 200.2  | 200.0  | 200.8  |
| Total                                     | 358.5 | 372.5  | 379.3 | 374.6  | 378.4  | 392.2 | 400.5  | 411.6 | 421.0 | 429.2  | 436.0  | 442.8  | 449.6  | 457.4  |
| growth rate                               | 0.6%  | 3.9%   | 1.8%  | -1.2%  | 1.0%   | 3.6%  | 2.1%   | 2.8%  | 2.3%  | 1.9%   | 1.6%   | 1.6%   | 1.5%   | 1.7%   |
| Uranium demand analysis                   |       |        |       |        |        |       |        |       |       |        |        |        |        |        |
| Operating reactors                        | 194.2 | 191.4  | 183.8 | 180.3  | 180.3  | 186.5 | 190.2  | 195.1 | 199.2 | 202.7  | 205.5  | 208.3  | 211.1  | 214.4  |
| Strategic inventory build                 |       | -      | -     | -      | -      | -     | -      | -     | -     |        |        |        |        | -      |
| Total demand                              | 194.2 | 191.4  | 183.8 | 180.3  | 180.3  | 186.5 | 190.2  | 195.1 | 199.2 | 202.7  | 205.5  | 208.3  | 211.1  | 214.4  |
| growth rate                               | 0.5%  | -1.4%  | -4.0% | -1.9%  | 0.0%   | 3.4%  | 1.9%   | 2.6%  | 2.1%  | 1.8%   | 1.4%   | 1.4%   | 1.3%   | 1.5%   |
| Market surplus (deficit)                  | 18.7  | 18.8   | 18.2  | 6.5    | (6.7)  | (5.6) | (11.3) | (4.3) | 4.9   | (6.7)  | (14.5) | (20.2) | (24.2) | (30.1) |
| Surplus (deficit) as % of global demand   | 10%   | 10%    | 10%   | 4%     | -4%    | -3%   | -6%    | -2%   | 2%    | -3%    | -7%    | -10%   | -11%   | -14%   |
| Change in market surplus (deficit)        | 0.5   | 0.1    | (0.6) | (11.7) | (13.2) | 1.1   | (5.7)  | 7.0   | 9.2   | (11.5) | (7.8)  | (5.7)  | (4.0)  | (5.9)  |
| Net contribution - Primary mine supply    | (7.4) | (16.8) | 1.7   | (18.5) | 4.8    | 11.6  | 0.9    | 14.5  | 14.2  | (4.0)  | (2.1)  | (1.3)  | (0.1)  | 2.7    |
| Net contribution - Secondary supply       | 8.8   | 14.1   | (9.9) | 3.4    | (18.0) | (4.4) | (2.9)  | (2.6) | (0.9) | (4.1)  | (2.9)  | (1.6)  | (1.1)  | (5.4)  |
| Net contribution - Uranium demand         | (0.9) | 2.8    | 7.6   | 3.4    | (0.0)  | (6.2) | (3.6)  | (4.9) | (4.1) | (3.5)  | (2.8)  | (2.8)  | (2.8)  | (3.3)  |
| Uranium Price Forecast (US\$/lb) - Spot   | 22.20 | 24.70  | 26.00 | 29.60  | 32.00  | 35.00 | 39.00  | 42.00 | 47.00 | 50.00  | 50.00  | 50.00  | 50.00  | 50.00  |

Source: UxC LLC, World Nuclear Association, Eight Capital estimates

#### Cameco Corp.

This research report (as defined in IIROC Rule 3400) is issued and approved for distribution in Canada by Eight Capital, a member of the Investment Industry Regulatory Organization of Canada, and the Canadian Investor Protection Fund. Eight Capital accepts responsibility for the dissemination of this report. Non-client recipients of the research report should not rely solely on the investment recommendations contained herein and should consult their own professional advisors. Eight Capital will not treat any non-client receiving this report as its own. Institutional clients who require additional information on securities discussed in this report should contact a qualified sales person at Eight Capital.

Eight Capital accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein.

This research report is being provided only to institutional clients of Eight Capital and is intended for informational purposes only. This research report is not an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. The information contained in this research report is prepared from publicly available information, internally developed data and other sources believed to be reliable, but has not been independently verified by Eight Capital. Eight Capital makes no representations or warranties with respect to the accuracy, correctness or completeness of such information and they should not be relied upon as such.

All estimates, opinions and recommendations expressed herein constitute judgments as of the date of this research report and are subject to change without notice. Eight Capital does not accept any obligation to update, modify or amend this research report or to otherwise notify a recipient of this research report in the event that any estimates, opinions and recommendations contained herein change or subsequently become inaccurate or if this research report is subsequently withdrawn.

Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Nothing in this research report constitutes legal, accounting or tax advice. Investors should consult with his or her independent legal or tax adviser in this regard.

**US Residents:** This report is provided to US residents under a chaperoning arrangement pursuant to Rule 15a-6 of the U.S. Securities Exchange Act of 1934 (the "Rule"). Eight Capital is a non-U.S. broker-dealer for the purposes of the Rule and is not registered with the Financial Industry Regulatory Authority, the Securities and Exchange Commission or any state securities regulatory authority.

Research produced and distributed by Eight Capital is distributed by Eight Capital to persons who are "major U.S. institutional investors" which is defined as a U.S. institutional investor or any other entity which owns or manages at least \$100 million in financial assets (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended). Research reports are not a solicitation to sell the securities discussed herein; however, should you choose to make an unsolicited transaction in such securities, we may refer you to our chaperone.

Eight Capital Corp. is a U.S. registered broker-dealer, a member of FINRA and an affiliate of Eight Capital. Eight Capital Corp. accepts responsibility for the contents of this research report, and its dissemination in the United States to certain institutional investors, subject to the terms and limitations as set out above. U.S. residents seeking to effect a transaction in any security discussed herein should contact an Eight Capital Corp. qualified person directly.

#### Registration of non-U.S. Analysts:

The authoring non-U.S. research analyst employed by Eight Capital who contributes to this report is not registered/qualified as a research analyst with FINRA; and,

The authoring non-U.S. research analyst(s) is not associated with the member firm and therefore not subject to the requirements of FINRA Rule 2241 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

**U.K. Residents:** The authoring analyst(s) who prepared this research report is employed by Eight Capital, a Canadian regulated entity. The report has been prepared and approved in accordance with regulatory standards in Canada and was not viewed for the purposes of the UK's Financial Services and Markets Act 2000. This report is not intended for use by and should not be directed to individual investors.

#### Dissemination of Research

Eight Capital's Research is distributed electronically through email, website (password protected) or hard copy. Dissemination of initial research reports and any subsequent research reports is made simultaneously to a pre-determined list of clients of Eight Capital's Institutional Sales and Trading representatives.

#### **Conflicts of Interest**

Eight Capital has written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research and other businesses. The compensation of each Research Analyst/Associate involved in the preparation of this research report is based competitively upon several criteria, including performance assessment criteria, the quality of research and the value of the services they provide to clients of Eight Capital. The Research Analyst compensation pool includes revenues from several sources, including sales, trading and investment banking. Research analysts and associates do not receive compensation based upon revenues from specific investment banking transactions.

Eight Capital generally restricts any research analyst/associate and any member of his or her household from executing trades in the securities of a company that such research analyst covers, with limited exception.

Should this research report provide web addresses of, or contain hyperlinks to, third party web sites, Eight Capital has not reviewed the contents of such links and takes no responsibility whatsoever for the contents of such web sites. Web addresses and/or hyperlinks are provided solely for the recipient's convenience and information, and the content of third party web sites is not in any way incorporated into this research report. Recipients who choose to access such web addresses or use such hyperlinks do so at their own risk.

Unless publications are specifically marked as research publications of Eight Capital, the views expressed therein (including recommendations) are those of the author and, if applicable, any named issuer or Investment Dealer alone, and have not been approved by, nor are they necessarily those of, Eight Capital. Eight Capital expressly disclaims any and all liability for the content of any publication that is not expressly marked as a research publication of Eight Capital.

Forward-looking statements are based on current expectations, estimates, forecasts and projections based on beliefs and assumptions made by the author. These statements involve risks and uncertainties and are not guarantees of future performance or results and no assurance can be given that these estimates and expectations will prove to have been correct, and actual outcomes and results may differ materially from what is expressed, implied or projected in such forward-looking statements.

## **Research Analyst Certification**

Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- the views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- his/her compensation is not and will not be directly related to the specific recommendations or views expressed by the Research Analyst in this research report;
- they have not affected a trade in a security of any class of the issuer whether directly or indirectly through derivatives within the 30-day period prior to the publication of this research report;
- they have not distributed or discussed this Research Report to/with the issuer, investment banking at Eight Capital or any other third party except for the sole purpose of verifying factual information; and
- they are unaware of any other potential conflicts of interest.

The Research Analyst involved in the preparation of this research report does not have any authority whatsoever (actual, implied or apparent) to act on behalf of any issuer mentioned in this research report.

## **Informal Comment**

Informal Comments are analysts' informal comments that are posted on the Eight Capital website. They generally pertain to news flow and do not contain any change in analysts' opinion, estimates, rating or target price. Any rating(s) and target price(s) in an Informal Comment are from prior formal published research reports. A link is provided in any Informal Comment to all company specific disclosures and analyst specific disclosures for companies under coverage, as well as general disclosures and disclaimers.

#### Presentations

Presentations do not include disclosures that are specific to analysts and specific to companies under coverage. Please refer to formal published research reports for company specific disclosures, analyst specific disclosures and valuation methodologies used in determining target prices for companies under coverage.

## Idea of Interest

Eight Capital has not initiated formal and continuous coverage of the companies mentioned in these publications, and maintain no recommendation, price target or earnings forecast. Statements and analysis in these publications are introductory in nature and may be published from time to time based on publicly available information.

**IIROC Rule 3400 Disclosures:** A link (<u>here</u>) is provided in all research reports delivered by electronic means to disclosures required under IIROC Rule 3400, including disclosures for sector research reports covering six or more issuers.

## **Explanation of Recommendations**

**Eight Capital target:** Represents the price target as required under IIROC Rule 3400. Valuation methodologies used in determining the price target(s) for the issuer(s) mentioned in this research report are contained in current and/or prior research. Eight Capital target N/A: a price target and/or NAV are not available if the analyst deems there are limited financial metrics upon which to base a reasonable valuation.

**Recommendations: BUY**: Total returns expected to be materially better than the overall market with higher return expectations needed for more risky securities. **NEUTRAL**: Total returns expected to be in line with the overall market. **SELL**: Total returns expected to be materially lower than the overall market. **TENDER**: The analyst recommends tendering shares to a formal tender offer. **UNDER REVIEW**: The analyst will place the rating and/or target price Under Review when there is a significant material event with further information pending; and/or when the analyst determines it is necessary to await adequate information that could potentially lead to a re-evaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

**SECURITY ABBREVIATIONS**: NVS (non-voting shares); RVS (restricted voting shares); RS (restricted shares); SVS (subordinate voting shares).



## **Eight Capital Equity Research Ratings:**

% of companies covered by Eight Capital in each rating category

As at June 30, 2021 Source: Eight Capital

<sup>%</sup> of companies within each rating category for which Eight Capital has provided investment banking services for a fee in the past 12 months.